BioSpace

Merck KGaA makes noise in hematology with $1.1B Silence buy

Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market.

By BioSpace

1 min read
Merck KGaA makes noise in hematology with $1.1B Silence buy
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights